Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPLAR: Organ Preservation in Rectal Cancer
NCT07070622Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in rectal cancer, sponsored by West China Hospital of Sichuan University. Started Nov 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07070622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070622.